Dr. Eric Joshua Schultz, MD

Dr. Schultz practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Schultz's NPI, 1568993707, was assigned on March 21, 2017. Dr. Schultz holds New York license 303464.

Dr. Schultz's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Schultz's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Medical Consultation Group. Dmand AI also links Dr. Schultz to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schultz practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Schultz's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Schultz is licensed in New York.

CMS data shows 568 Medicare services from Dr. Schultz across 5 procedure codes in 2024, for 179 Medicare patients. Medicare paid $56,542 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 179 Medicare patients who saw Dr. Schultz in 2024. The largest group is 65 to 74, with 80 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 3.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Schultz's median patient age at 70, with 58% women.

In 2024, Dr. Schultz wrote 25 Medicare Part D claims for 16 patients. 80% of them were for generic drugs. They cover 20 drugs, with $44,563 in total drug cost. In 2019, CMS named 544 claims across 25 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Schultz for performance year 2024, reported as part of a group. Dr. Schultz accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 10 papers to Dr. Schultz, published from 2014 to 2022. 2015 was the busiest year, with 3. The most frequent topics are Disease Models, Animal, Heart and Lisinopril. Dr. Schultz has published most often in Front Physiol. Dr. Schultz's most frequent co-authors are Tallib Adam Karaze, DO, Eric Jeffrey Schultz, MD and Celso E. Gomez-Sanchez, MD.

CMS Open Payments shows 1 general payment to Dr. Schultz from 1 drug or device company in 2023. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $20.